Armata Pharmaceuticals Inc. Focuses on Innovative Bacteriophage Therapies

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company based in Marina Del Rey, United States, is making strides in the healthcare sector with its focus on developing novel bacteriophage-based therapies. The company’s mission is to improve human health by addressing multidrug-resistant bacterial infections and preventable infectious diseases of the microbiome. By concentrating on these critical areas, Armata Pharmaceuticals aims to serve patients in California and beyond, potentially making a significant impact on global health.

As of August 10, 2025, Armata Pharmaceuticals is listed on the NYSE American with a close price of $2.36 per share. The company’s market capitalization stands at $88,670,000 USD. Over the past year, the stock has experienced fluctuations, reaching a 52-week high of $2.96 on November 12, 2024, and a 52-week low of $0.90 on April 10, 2025. The price-to-earnings ratio is currently at -21.509, reflecting the company’s ongoing investment in research and development without immediate profitability.

Armata Pharmaceuticals operates within the health care sector, specifically within the biotechnology industry. The company’s innovative approach involves leveraging both natural and synthetic bacteriophages to combat bacterial infections that are resistant to multiple drugs. This focus on bacteriophage therapy positions Armata Pharmaceuticals at the forefront of addressing some of the most pressing challenges in infectious disease treatment today.

The company’s efforts are particularly significant given the rising concern over antibiotic resistance, which poses a substantial threat to public health worldwide. By developing therapies that target the microbiome and prevent infections, Armata Pharmaceuticals is contributing to the broader goal of enhancing patient outcomes and reducing the burden of infectious diseases.

As Armata Pharmaceuticals continues its clinical trials and research initiatives, the company remains committed to its mission of improving human health through innovative biotechnological solutions. With its strategic focus and dedicated team, Armata Pharmaceuticals is poised to make meaningful advancements in the treatment of multidrug-resistant infections and the prevention of microbiome-related diseases.